
    
      This research study is a Phase I clinical trial, which tests the safety of an investigational
      intervention and also tries to define the appropriate dose of the investigational
      intervention to use for further studies. "Investigational" means that the intervention is
      being studied.

      The U.S. Food and Drug Administration (FDA) has not approved CIML NK Cell Infusion as a
      treatment for relapsed disease.
    
  